Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05219539
Other study ID # ATP-LRG-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 11, 2021
Est. completion date December 20, 2021

Study information

Verified date May 2022
Source Fujian Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to evaluate the outcomes of the advanced training program for laparoscopic radical gastrectomy (ATP-LRG). The research subjects are the trainees who participated in this training program.


Description:

Written informed consent is not required because of the observational and anonymous nature of this study. ATP-LRG is a national training program carried out by Fujian Medical University Union Hospital. Each training lasts about 1.5 days, which includes 1) detailed technique description; 2) prevention and solving of intraoperative complications; 3) live surgery performance; 4) theory and practice of clinical research; 5) comments on trainees' videos; and 6) questions, answers and discussions. In this study, 875 trainees who participated in ATP-LRG from January 2015 to October 2020 were interviewed using electronic questionnaires. Using a repeated-measures design to examine differences in outcomes before and after participating in the training. Questionnaire Star (Changsha Ranxing Information Technology Co., Ltd), a most widely used professional online questionnaire software platform in China, was used to design and create a link to the questionnaire. The questionnaire's link was sent to each trainee via WeChat (Tencent Holdings Limited), the most commonly used social networking software in China.


Recruitment information / eligibility

Status Completed
Enrollment 1355
Est. completion date December 20, 2021
Est. primary completion date December 2, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Participated in ATP-LRG between January 2015 and October 2020 - Have contact information Exclusion Criteria: - Repeated participation in ATP-LRG - Refuse to fill out the questionnaire

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Fujian Medical University Union Hospital Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of general surgical skills score Change of general surgical skills score = posttraining general surgical skills score - pretraining general surgical skills score. Scores were evaluated using questionares. One year after participating in ATP-LRG
Secondary Changes of laparoscopic gastrectomy acceptance score Changes of laparoscopic gastrectomy acceptance score = posttraining laparoscopic gastrectomy acceptance score - pretraining laparoscopic gastrectomy acceptance score. Scores were evaluated using questionares. One year after participating in ATP-LRG
Secondary Changes of clinical research possibilities score Changes of clinical research possibilities score= posttraining clinical research possibilities score - pretraining clinical research possibilities score. Scores were evaluated using questionares. One year after participating in ATP-LRG
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2